ID   CRNA_PSEPU              Reviewed;         260 AA.
AC   P83772; Q52548;
DT   05-APR-2011, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2004, sequence version 1.
DT   24-JUN-2015, entry version 45.
DE   RecName: Full=Creatinine amidohydrolase;
DE            EC=3.5.2.10;
DE   AltName: Full=Creatininase;
GN   Name=crnA;
OS   Pseudomonas putida (Arthrobacter siderocapsulatus).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Pseudomonas.
OX   NCBI_TaxID=303;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-6.
RC   STRAIN=PS-7;
RX   PubMed=7670196; DOI=10.1271/bbb.59.1331;
RA   Yamamoto K., Oka M., Kikuchi T., Emi S.;
RT   "Cloning of the creatinine amidohydrolase gene from Pseudomonas sp.
RT   PS-7.";
RL   Biosci. Biotechnol. Biochem. 59:1331-1332(1995).
RN   [2]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.
RC   STRAIN=C-83;
RX   PubMed=500580;
RA   Rikitake K., Oka I., Ando M., Yoshimoto T., Tsuru D.;
RT   "Creatinine amidohydrolase (creatininase) from Pseudomonas putida.
RT   Purification and some properties.";
RL   J. Biochem. 86:1109-1117(1979).
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 2-260 IN COMPLEX WITH ZINC,
RP   COFACTOR, AND SUBUNIT.
RX   PubMed=12946365; DOI=10.1016/S0022-2836(03)00860-X;
RA   Beuth B., Niefind K., Schomburg D.;
RT   "Crystal structure of creatininase from Pseudomonas putida: a novel
RT   fold and a case of convergent evolution.";
RL   J. Mol. Biol. 332:287-301(2003).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF APOENZYME AND COMPLEXES WITH
RP   CREATINE; ZINC AND MANGANESE, COFACTOR, SUBUNIT, AND CATALYTIC
RP   MECHANISM.
RX   PubMed=15003455; DOI=10.1016/j.jmb.2004.01.022;
RA   Yoshimoto T., Tanaka N., Kanada N., Inoue T., Nakajima Y.,
RA   Haratake M., Nakamura K.T., Xu Y., Ito K.;
RT   "Crystal structures of creatininase reveal the substrate binding site
RT   and provide an insight into the catalytic mechanism.";
RL   J. Mol. Biol. 337:399-416(2004).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (1.78 ANGSTROMS) OF WILD-TYPE IN COMPLEX WITH
RP   1-METHYLGUANIDINE INHIBITOR AND MUTANTS ALA-154; PHE-154; PHE-174 AND
RP   GLN-122 IN COMPLEX WITH CREATINE; ZINC AND MANGANESE, CATALYTIC
RP   ACTIVITY, KINETIC PARAMETERS, CATALYTIC MECHANISM, AND MUTAGENESIS OF
RP   TYR-121; GLU-122; TRP-154; TRP-174 AND GLU-183.
RX   PubMed=20043918; DOI=10.1016/j.jmb.2009.12.045;
RA   Yamashita K., Nakajima Y., Matsushita H., Nishiya Y., Yamazawa R.,
RA   Wu Y.F., Matsubara F., Oyama H., Ito K., Yoshimoto T.;
RT   "Substitution of Glu122 by glutamine revealed the function of the
RT   second water molecule as a proton donor in the binuclear metal enzyme
RT   creatininase.";
RL   J. Mol. Biol. 396:1081-1096(2010).
CC   -!- FUNCTION: Cyclic amidohydrolase that catalyzes the reversible
CC       conversion of creatinine to creatine. Is also active toward
CC       glycocyamidine, though the reaction rate is very low, but it is
CC       completely inert toward hydantoin and its derivatives.
CC       {ECO:0000269|PubMed:500580}.
CC   -!- CATALYTIC ACTIVITY: Creatinine + H(2)O = creatine.
CC       {ECO:0000269|PubMed:20043918, ECO:0000269|PubMed:500580}.
CC   -!- COFACTOR:
CC       Note=Binds 2 Zn(2+) ions per subunit. The Zn(2+) in the metal 1
CC       binding site can be replaced with Mn(2+); however, the second zinc
CC       in metal binding site 2 is much more tightly bound and can not be
CC       replaced. The enzyme with one zinc and one manganese ion is more
CC       active than that with two zinc ions. {ECO:0000269|PubMed:12946365,
CC       ECO:0000269|PubMed:15003455};
CC   -!- ENZYME REGULATION: Is markedly inactivated in vitro by heavy metal
CC       ions, N-bromosuccinimide, ethoxyformic anhydride, and dye-
CC       sensitized photooxidation. {ECO:0000269|PubMed:500580}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=26 mM for creatinine {ECO:0000269|PubMed:20043918,
CC         ECO:0000269|PubMed:500580};
CC         KM=130 mM for creatine {ECO:0000269|PubMed:20043918,
CC         ECO:0000269|PubMed:500580};
CC         KM=200 mM for glycocyamidine {ECO:0000269|PubMed:20043918,
CC         ECO:0000269|PubMed:500580};
CC         Vmax=390 umol/min/mg enzyme for the forward reaction (creatine
CC         formation) {ECO:0000269|PubMed:20043918,
CC         ECO:0000269|PubMed:500580};
CC         Vmax=1510 umol/min/mg enzyme for the reverse reaction
CC         (creatinine formation) {ECO:0000269|PubMed:20043918,
CC         ECO:0000269|PubMed:500580};
CC         Vmax=3.7 umol/min/mg enzyme with glycocyamidine as substrate
CC         {ECO:0000269|PubMed:20043918, ECO:0000269|PubMed:500580};
CC       pH dependence:
CC         Optimum pH is 7-9 for the forward and reverse reactions.
CC         {ECO:0000269|PubMed:500580};
CC       Temperature dependence:
CC         Retains 75% of the activity after incubation at 75 degrees
CC         Celsius for 30 minutes. {ECO:0000269|PubMed:500580};
CC   -!- PATHWAY: Amine and polyamine degradation; creatinine degradation.
CC   -!- SUBUNIT: Homohexamer; trimer of dimers.
CC       {ECO:0000269|PubMed:12946365, ECO:0000269|PubMed:15003455,
CC       ECO:0000269|PubMed:20043918}.
CC   -!- MISCELLANEOUS: The proposed catalytic mechanism involves two water
CC       molecules. The first molecule is a hydroxide ion that is bound as
CC       a bridge between the two metal ions and attacks the carbonyl
CC       carbon of the substrate. The second water molecule, that is bound
CC       to the carboxyl group of Glu-122 and to the metal 1, functions as
CC       a proton donor in catalysis.
CC   -!- SIMILARITY: Belongs to the creatininase superfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D45424; BAA08265.1; -; Genomic_DNA.
DR   PIR; T48846; T48846.
DR   PDB; 1J2T; X-ray; 1.80 A; A/B/C/D/E/F=1-260.
DR   PDB; 1J2U; X-ray; 1.85 A; A/B/C/D/E/F=1-260.
DR   PDB; 1Q3K; X-ray; 2.10 A; A/B/C/D/E/F=2-260.
DR   PDB; 1V7Z; X-ray; 1.60 A; A/B/C/D/E/F=1-260.
DR   PDB; 3A6D; X-ray; 1.90 A; A/B/C/D/E/F=1-260.
DR   PDB; 3A6E; X-ray; 2.00 A; A/B/C/D/E/F=1-260.
DR   PDB; 3A6F; X-ray; 1.78 A; A/B/C/D/E/F=1-260.
DR   PDB; 3A6G; X-ray; 2.00 A; A/B/C/D/E/F=1-260.
DR   PDB; 3A6H; X-ray; 2.00 A; A/B/C/D/E/F=1-260.
DR   PDB; 3A6J; X-ray; 2.00 A; A/B/C/D/E/F=1-260.
DR   PDB; 3A6K; X-ray; 2.20 A; A/B/C/D/E/F=1-260.
DR   PDB; 3A6L; X-ray; 2.00 A; A/B/C/D/E/F=1-260.
DR   PDBsum; 1J2T; -.
DR   PDBsum; 1J2U; -.
DR   PDBsum; 1Q3K; -.
DR   PDBsum; 1V7Z; -.
DR   PDBsum; 3A6D; -.
DR   PDBsum; 3A6E; -.
DR   PDBsum; 3A6F; -.
DR   PDBsum; 3A6G; -.
DR   PDBsum; 3A6H; -.
DR   PDBsum; 3A6J; -.
DR   PDBsum; 3A6K; -.
DR   PDBsum; 3A6L; -.
DR   ProteinModelPortal; P83772; -.
DR   SMR; P83772; 3-259.
DR   BioCyc; MetaCyc:MONOMER-10962; -.
DR   BRENDA; 3.5.2.10; 5092.
DR   UniPathway; UPA00274; -.
DR   EvolutionaryTrace; P83772; -.
DR   GO; GO:0047789; F:creatininase activity; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006601; P:creatine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006602; P:creatinine catabolic process; IDA:UniProtKB.
DR   Gene3D; 3.40.50.10310; -; 1.
DR   InterPro; IPR031034; Creatininase.
DR   InterPro; IPR024087; Creatininase-like_dom.
DR   InterPro; IPR003785; Creatininase/forma_Hydrolase.
DR   Pfam; PF02633; Creatininase; 1.
DR   SUPFAM; SSF102215; SSF102215; 1.
DR   TIGRFAMs; TIGR04448; creatininase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; Hydrolase; Manganese;
KW   Metal-binding; Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000305|PubMed:7670196}.
FT   CHAIN         2    260       Creatinine amidohydrolase.
FT                                /FTId=PRO_0000406934.
FT   REGION      174    178       Substrate binding.
FT   METAL        34     34       Zinc or manganese 1.
FT                                {ECO:0000269|PubMed:12946365,
FT                                ECO:0000269|PubMed:20043918}.
FT   METAL        36     36       Zinc 2; via tele nitrogen.
FT                                {ECO:0000269|PubMed:12946365,
FT                                ECO:0000269|PubMed:20043918}.
FT   METAL        45     45       Zinc 2. {ECO:0000269|PubMed:12946365,
FT                                ECO:0000269|PubMed:20043918}.
FT   METAL        45     45       Zinc or manganese 1.
FT                                {ECO:0000269|PubMed:12946365,
FT                                ECO:0000269|PubMed:20043918}.
FT   METAL       120    120       Zinc or manganese 1; via pros nitrogen.
FT                                {ECO:0000269|PubMed:12946365,
FT                                ECO:0000269|PubMed:20043918}.
FT   METAL       183    183       Zinc 2. {ECO:0000269|PubMed:12946365,
FT                                ECO:0000269|PubMed:20043918}.
FT   BINDING      78     78       Substrate; via carbonyl oxygen.
FT   BINDING     121    121       Substrate; via amide nitrogen.
FT   SITE        122    122       Coordinates a catalytic water molecule.
FT   MUTAGEN     121    121       Y->A: 30-fold decrease in catalytic
FT                                efficiency.
FT                                {ECO:0000269|PubMed:20043918}.
FT   MUTAGEN     122    122       E->Q: 700-fold decrease in catalytic
FT                                efficiency. No ion in metal binding site
FT                                1. {ECO:0000269|PubMed:20043918}.
FT   MUTAGEN     154    154       W->A: Loss of activity.
FT                                {ECO:0000269|PubMed:20043918}.
FT   MUTAGEN     154    154       W->F: 340-fold decrease in catalytic
FT                                efficiency.
FT                                {ECO:0000269|PubMed:20043918}.
FT   MUTAGEN     174    174       W->A: Nearly no activity.
FT                                {ECO:0000269|PubMed:20043918}.
FT   MUTAGEN     174    174       W->F: 2-fold decrease in catalytic
FT                                efficiency.
FT                                {ECO:0000269|PubMed:20043918}.
FT   MUTAGEN     178    178       H->A: Loss of activity.
FT   MUTAGEN     183    183       E->Q: Loss of activity.
FT                                {ECO:0000269|PubMed:20043918}.
FT   HELIX         7      9       {ECO:0000244|PDB:1V7Z}.
FT   HELIX        12     20       {ECO:0000244|PDB:1V7Z}.
FT   STRAND       26     30       {ECO:0000244|PDB:1V7Z}.
FT   STRAND       38     40       {ECO:0000244|PDB:1V7Z}.
FT   HELIX        44     60       {ECO:0000244|PDB:1V7Z}.
FT   HELIX        76     79       {ECO:0000244|PDB:1V7Z}.
FT   STRAND       84     86       {ECO:0000244|PDB:1V7Z}.
FT   HELIX        92    109       {ECO:0000244|PDB:1V7Z}.
FT   STRAND      113    118       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       121    123       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       124    140       {ECO:0000244|PDB:1V7Z}.
FT   STRAND      147    152       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       153    156       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       160    166       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       174    176       {ECO:0000244|PDB:3A6F}.
FT   STRAND      178    180       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       181    190       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       192    194       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       197    199       {ECO:0000244|PDB:1V7Z}.
FT   STRAND      210    215       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       218    220       {ECO:0000244|PDB:1V7Z}.
FT   HELIX       235    256       {ECO:0000244|PDB:1V7Z}.
SQ   SEQUENCE   260 AA;  28569 MW;  E530A7513F57A762 CRC64;
     MSKSVFVGEL TWKEYEARVA AGDCVLMLPV GALEQHGHHM CMNVDVLLPT AVCKRVAERI
     GALVMPGLQY GYKSQQKSGG GNHFPGTTSL DGATLTGTVQ DIIRELARHG ARRLVLMNGH
     YENSMFIVEG IDLALRELRY AGIQDFKVVV LSYWDFVKDP AVIQQLYPEG FLGWDIEHGG
     VFETSLMLAL YPDLVDLDRV VDHPPATFPP YDVFPVDPAR TPAPGTLSSA KTASREKGEL
     ILEVCVQGIA DAIREEFPPT
//
